US4986256A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of paramagnetic metalloporphyrins as contrast agents for tumors in MRI imaging
Assignee: United States, AS REPRESENTED BY SECRETARY IOF DEPARTMENT OF HEALTH AND HUMAN SERVICES
•
Filing: 1985-02-28
•
Granted: 1991-01-22
•
Expires: 2005-02-28
Abstract
Abstract Water-soluble paramagnetic metalloporphyrins are used as contrast enhancing agents for magnetic resonance imaging. These agents exhibit excellent localization, non-toxicity and suprisingly high contrast enhancement in magnetic resonance imaging applications.
Inventors
- 👤 Jack S. Cohen
- 👤 Chi-wan Chen
- 👤 Charles E. Myers
- 👤 Miriam Sohn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 16:04
CPC Classifications
G; G01; G01R; G01R33/00; G01R33/20; G01R33/44; G01R33/48; G01R33/54; G01R33/56; G01R33/5601; A; A61; A61K; A61K49/00; A61K49/06; Y; Y10; Y10T; Y10T436/00; Y10T436/24
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
78 words
A method of enhancing an image obtained from magnetic resonance imaging of a region containing a malignant tumorous growth comprising the steps of administering to a subject a non-lethal amount of a water-soluble paramagnetic Mn(III) porphyrin, or a pharmaceutically acceptable acid form or salt thereof effective to significantly enhance the contrast in a magnetic resonance image between said malignant tumorous growth and the remainder of said image; and then imaging said region of said subject by magnetic resonance.
Claim 2
Independent Claim
78 words
A method of enhancing an image obtained from magnetic resonance imaging of a region containing a malignant tumorous growth comprising the steps of administering to a subject a non-lethal amount of a water-soluble paramagnetic Mn(III) porphyrin, or a pharmaceutically acceptable acid form or salt thereof effective to significantly enhance the contrast in a magnetic resonance image between said malignant tumorous growth and the remainder of said image; and then imaging said region of said subject by magnetic resonance.
Claim 3
Dependent Claim
67 words
The method of claim 1 wherein the porphyrin portion of said metalloporphyrin is tetrasulfonated tetraphenylsulfonyl porphyrin, tetra(N-methyl-4-pyridyl) porphyrin, methylated tetrasulfonated tetraphenylsulfonyl porphyrin or tetra (N-methylanilinium) porphyrin and pharmaceutically acceptable acid forms and salts thereof effective to significantly enhance the contrast in a magnetic resonance image between said malignant tumorous growth and the remainder of said image; and then imaging said region of said subject by magnetic resonance.
Claim 4
Dependent Claim
14 words
The method of claim 2, wherein said metalloporphyrin is administered intervenously or by infusion.
Claim 5
Dependent Claim
16 words
The method of claim 3, wherein the porphyrin portion of said metalloporphyrin is tetrasulfonated tetraphenylsulfonyl porphyrin.
References Cited (Backward Citations)
US4298590A
Cited
US4393071A
Cited
US4136683A
Cited
US4266549A
Cited
US4354499A
Cited
US4411270A
Cited
US4386087A
Cited
EP0071564A1
Cited
GB2109407A
Cited
EP0133603A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-21 | 1994-07-23 | 1995-01-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-21 | 1998-07-23 | 1999-01-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-21 | 2002-07-23 | 2003-01-22 | $7700.00 | Window Closed / Lapsed |